Oncothyreon is going it alone with Array’s former breast cancer contender

Damian Garde Moving on from the slow demise of its Merck KGaA-partnered cancer vaccine, Seattle's Oncothyreon has bought out co-developer Array BioPharma, acquiring exclusive rights ...

Novartis’ bid to widen Afinitor’s breast cancer reach falls short in PhIII

Carly Helfand Novartis' Afinitor already boasts an indication in advanced HR-positive, HER2-negative breast cancer, and the pharma giant was hoping to double up by adding a nod ...

Jazz heads to the FDA with its $1B rare disease drug

Damian Garde Jazz Pharmaceuticals has kicked off a rolling FDA submission for defibrotide, a rare disease treatment acquired in its $ 1 billion buyout of Gentium. FierceBiotech News

Novartis psoriasis prospect tops J&J’s fast-growing Stelara in PhIII

Carly Helfand J&J's Stelara has some psoriasis competition waiting in the wings: On Friday, Novartis announced its Phase III prospect, to be marketed as Cosentyx, had bested ...

Ex-Pfizer SVP takes the helm at BioClinica

Alok Saboo FierceBiotech News

Abbott, unfazed by political tensions, closes deal for Russia’s Veropharm

Carly Helfand Mounting political tensions between Russia and the West may have recently scared Germany's Fresenius out of a partnership in the country. But they won't spook ...

Shire chief: We want to be like Gilead, Biogen and Celgene

Damian Garde On the rebound after a dalliance with AbbVie and its $ 55 billion red herring, Shire CEO Flemming Ornskov is back on the offensive, talking up his company's potential ...

Actavis plan to stop making original Namenda derailed by court

Eric Palmer A federal judge in New York has decided Actavis CEO Brent Saunders' plan to move patients to a new version of its Alzheimer's treatment Namenda IR by stopping production ...

Merck wins FDA approval for Gardasil’s heir

Damian Garde Merck won the FDA's blessing for a next-generation HPV vaccine designed to usurp Gardasil, putting it in line for billions in revenue. FierceBiotech News

Merck’s next-gen Gardasil wins FDA approval

Tracy Staton Merck's Gardasil follow-up is here, meaning blockbuster sales are likely on the way. But they'll come at the expense of the previous iteration. FiercePharma ...

Merck’s PD-1 star Keytruda shines at ASH, but lags behind Bristol-Myers’ rival

John Carroll FierceBiotech News

Sanofi Chairman says French tax burden a killer for attracting execs

Eric Palmer Sanofi Chairman Serge Weinberg, who must replace Chris Viehbacher after ousting the outspoken CEO, has publicly expressed his own exasperation with France, saying its high ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS